OR WAIT null SECS
In addition to newly added advances with hemodynamic assessment and obstetric measurements, Lumify also offers a B-line quantification tool and AI-enhanced algorithms that may bolster ultrasound lung imaging in severe COVID-19 cases.
Building upon the applications of its handheld, point-of-care ultrasound device Lumify, Philips noted the modality now features advanced hemodynamic assessment as well as obstetric measurement capabilities.
The addition of Pulse Wave Doppler to Lumify enables clinicians to differentiate between arterial and venous blood flow and quantify hemodynamic function. Philips said the hemodynamic measurement capabilities of Lumify can facilitate timely interventions in cardiology and emergency medicine settings. The use of obstetric measurements may also aid in identifying high-risk pregnancies, according to the company.
“With the addition of Pulse Wave Doppler and enhanced obstetric measurements, we have increased the number of markers on which diagnoses can be made to deliver high quality imaging and enhance the evaluation and effectiveness of treatment in real time,” noted Matthijs Groot Wassink, general manager of point of care ultrasound at Philips.
Noting the key role of lung ultrasound in diagnosing pneumonia, a common complication of COVID-19, Philips maintained that Lumify is the only point-of-care ultrasound device that features artificial intelligence (AI)-enhanced B-line quantification. The company said the ability of this technology to assess B-lines in lung fluid may be beneficial for patients with severe cases of COVID-19 infection.